Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02038946
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy with both CD20 antibody and an alkylating agent.

Key Dates

Start date
Mar 26, 2014
Status verified
Dec 2021
Primary completion
May 17, 2017
Completion
Dec 28, 2020

Study Design

Enrollment
116 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1: Nivolumab
    Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity

Primary Outcome Measure

Overall Response Rate (ORR) as Determined by IRRC [ Time Frame: From Week 9 until documented disease progression or study discontinuation (assessed up to June 2017, approximately 38 months) ]

Locations (12)

FacilityCityStateZIPSite coordinators
Mayo Clinic ArizonaPhoenixArizona85054-
Division Of Hematology & Oncology Ctr. For Health SciencesLos AngelesCalifornia90095-
Winship Cancer Institute.AtlantaGeorgia30322-
Beth Israel Deaconess Medical Center (BIDMC)BostonMassachusetts02215-
Dana Farber Cancer InstituteBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02215-
Mayo ClinicRochesterMinnesota55905-
Weill Cornell Medical CollegeNew YorkNew York10021-
Duke University Medical CenterDurhamNorth Carolina27710-
Vanderbilt University Medical CenterNashvilleTennessee37232-
MD Anderson Cancer CenterHoustonTexas77030-
Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in Phoenix, AZ

By research site
Mayo Clinic Arizona· Phoenix, AZDivision Of Hematology & Oncology Ctr. For Health Sciences· Los Angeles, CAWinship Cancer Institute.· Atlanta, GABeth Israel Deaconess Medical Center (BIDMC)· Boston, MADana Farber Cancer Institute· Boston, MAMassachusetts General Hospital· Boston, MA

Related Studies